Bioorganic & Medicinal Chemistry Letters 2008-11-15

Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase.

Wooyoung Hur, Anastasia Velentza, Sungjoon Kim, Laura Flatauer, Xinnong Jiang, David Valente, Daniel E Mason, Melissa Suzuki, Brad Larson, Jianming Zhang, Anna Zagorska, Michael Didonato, Advait Nagle, Markus Warmuth, Steven P Balk, Eric C Peters, Nathanael S Gray

文献索引：Bioorg. Med. Chem. Lett. 18(22) , 5916-9, (2008)

全文：HTML全文

摘要

Irreversible HER/erbB inhibitors selectively inhibit HER-family kinases by targeting a unique cysteine residue located within the ATP-binding pocket. Sequence alignment reveals that this rare cysteine is also present in ten other protein kinases including all five Tec-family members. We demonstrate that the Tec-family kinase Bmx is potently inhibited by irreversible modification at Cys496 by clinical stage EGFR inhibitors such as CI-1033. This cross-reactivity may have significant clinical implications.